IP Library Granted Patent US 12,012,401
Granted Patent B2
US 12,012,401 · App. 17/205,558 · Granted Jun 18, 2024

Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide

Inventor: Sunil Kumar KC (San Diego, CA)
Assignee: BioSplice Therapeutics, Inc.
C07D471/04C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,012,401
App. No.
17/205,558
Granted
Jun 18, 2024
Kind
B2
Abstract

Provided herein is a synthetic process for preparing a compound of Formula (1). The disclosure also provides useful intermediates and salts, amorphous and polymorph forms of the compound of Formula (1). These compounds are useful for various disease including cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, and osteoarthritis as well as Wnt-related diseases.

Claims (34)

1. A process for preparing a polymorph form of a compound of Formula (1)

the process comprising:

(a) reacting a compound of Formula (8)

or a salt thereof, with bis(pinacolato)diboron and Pd(dppf)Cl 2 to produce a compound of Formula (9)

or a salt thereof;

(b) reacting the compound of Formula (9), or the salt thereof, with a compound of Formula (10)

or a salt thereof, Pd(PPh 3 ) 4 and K 3 PO 4 to prepare a compound of Formula (11)

or a salt thereof,

(c) reacting the compound of Formula (11), or the salt thereof, with a compound of Formula (6)

or a salt thereof, to prepare a compound of Formula (12)

or a salt thereof;

(d) deprotecting the compound of Formula (12), or the salt thereof, to prepare the compound of Formula (1), or a salt thereof, wherein deprotecting the compound of Formula (12) to prepare the compound of Formula (1) comprises reacting the compound of Formula (12) with trifluoroacetic acid;

(e) reslurrying the compound of Formula (1) in a solvent, wherein the solvent is selected from acetonitrile, n-butyl acetate, n-butanol, dichloromethane (DCM), heptane, isopropyl alcohol, methanol, methyl acetate (MA), methyl tert-butyl ether (MtBE), methyl isobutyl ketone (MIRK), toluene, water, and a mixture thereof; wherein reslurrying is performed at a temperature of about room temperature to about 50° C.; wherein reslurrying is performed for a time of about 10 hours to about 80 hours;

(f) filtering to provide the compound of Formula (1) as a residual solid;

(g) drying the residual solid;

(h) reslurrying the residual solid in a solvent to generate the polymorph Form 2, wherein the reslurrying is performed at room temperature, wherein the solvent is ethanol/water, and wherein the water is present in an amount of about 5% by weight; and

(i) filtering to provide the polymorph as a residual solid; wherein the polymorph Form 2 has an XRPD pattern with at least peaks at °2θ positions of 7.0±0.2, 21.5±0.2, and 22.0±0.2.

2. The process of claim 1 , wherein the trifluoroacetic acid in step (d) is neat trifluoroacetic acid.

3. The process of claim 1 , wherein the reslurrying in step (e) is performed at room temperature.

4. The process of claim 1 , wherein the reslurrying in step (e) is performed at a temperature of about 50° C.

5. The process of claim 1 , wherein the reslurrying in step (e) is performed at a temperature of about 30° C. to about 35° C.

6. The process of claim 1 , wherein the reslurrying in step (e) is performed for a time of about 58 hours to about 80 hours.

7. The process of claim 6 , wherein the solvent in step (e) is selected from methanol, water, and a mixture thereof.

8. The process of claim 7 , wherein the solvent in step (e) is 90% methanol/water.

9. The process of claim 7 , wherein the solvent in step (e) is methanol; and wherein the reslurrying is performed at a temperature of about 50° C.

10. The process of claim 1 , wherein the drying in step (g) is performed under vacuum.

11. The process of claim 10 , wherein the drying in step (g) is at a temperature of between about 60° C. and 90° C.

12. The process of claim 11 , wherein the drying in step (g) is at a temperature of about 75° C.

13. The process of claim 1 , wherein the polymorph Form 2 in step (i) has an XRPD pattern with at least peaks at °2θ positions 7.0±0.2, 18.9±0.2, 21.5±0.2, 22.0±0.2, and 24.2±0.2.

14. The process of claim 13 , wherein the polymorph Form 2 in step (i) has an XRPD pattern with at least peaks at °2θ positions 7.0±0.2, 10.4±0.2, 14.1±0.2, 17.6±0.2, 18.9±0.2, 19.2±0.2, 21.5±0.2, 22.0±0.2, 24.2±0.2, and 26.4±0.2.

15. The process of claim 1 , wherein the polymorph Form 2 exhibits an endotherm between about 220-230° C. as measured by DSC.

16. The process of claim 1 , wherein the polymorph Form 2 exhibits an exotherm between about 233-238° C. as measured by DSC.

17. The process of claim 1 , wherein the polymorph Form 2 exhibits an exotherm between about 290-295° C. as measured by DSC.

18. The process of claim 1 , wherein the polymorph Form 2 undergoes a weight loss of about 2.7% between about 36° C. to about 116° C., as measured by TGA.

Assignments (3)
SECURITY INTEREST Recorded Sep 14, 2022
From: BIOSPLICE THERAPEUTICS, INC.
To: VICKERS VENTURE FUND VI PTE. LTD.; VICKERS VENTURE FUND VI (PLAN) PTE. LTD.; VICKERS-SPLICE CO-INVESTMENT LLC; MED-PATHWAYS II LIMITED
Reel/Frame 061433/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2021
From: KC, SUNIL KUMAR
To: SAMUMED, LLC
Reel/Frame 055699/0974 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2021
From: SAMUMED, LLC
To: BIOSPLICE THERAPEUTICS, INC.
Reel/Frame 055700/0010 →
Continuity (6)
Continuation 16813021 · Mar 9, 2020
Continuation 16115222 · Aug 28, 2018
Continuation 15611150 · Jun 1, 2017
Provisional Application 62418657 · Nov 7, 2016
Provisional Application 62344170 · Jun 1, 2016
Related Publication 20220024914A1 · Jan 27, 2022